Cytek Price To Sales Ratio vs Pe Ratio Analysis

CTKB Stock

USD 6.83 0.26 3.96%

Cytek Biosciences financial indicator trend analysis is way more than just evaluating Cytek Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytek Biosciences is a good investment. Please check the relationship between Cytek Biosciences Price To Sales Ratio and its Pe Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

Price To Sales Ratio vs Pe Ratio

Price To Sales Ratio vs Pe Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytek Biosciences Price To Sales Ratio account and Pe Ratio. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Cytek Biosciences' Price To Sales Ratio and Pe Ratio is -0.55. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Pe Ratio in the same time period over historical financial statements of Cytek Biosciences, assuming nothing else is changed. The correlation between historical values of Cytek Biosciences' Price To Sales Ratio and Pe Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Cytek Biosciences are associated (or correlated) with its Pe Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pe Ratio has no effect on the direction of Price To Sales Ratio i.e., Cytek Biosciences' Price To Sales Ratio and Pe Ratio go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cytek Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cytek Biosciences sales, a figure that is much harder to manipulate than other Cytek Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Pe Ratio

Most indicators from Cytek Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytek Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.The current year's Enterprise Value is expected to grow to about 1.9 B, whereas Tax Provision is forecasted to decline to (1.7 M).

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	5.7M	9.2M	10.6M	11.1M
Interest Income	4.6M	7.6M	8.7M	9.2M

Depreciation And Amortization Interest Income

Cytek Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.99	0.93	0.99	0.95	0.96	0.87	0.83	-0.83	0.79	0.85	0.89	0.87	0.98	0.48	0.98	0.92	0.91	0.98	0.68	-0.54	0.93	0.93	0.93	-0.29	0.99
Other Current Liab	0.99		0.97	0.95	0.96	0.94	0.91	0.86	-0.75	0.74	0.86	0.82	0.9	0.96	0.43	0.93	0.96	0.91	0.96	0.73	-0.47	0.96	0.96	0.9	-0.2	0.96
Total Current Liabilities	0.93	0.97		0.91	0.97	0.9	0.93	0.9	-0.58	0.58	0.77	0.68	0.92	0.9	0.26	0.83	1.0	0.91	0.93	0.78	-0.52	1.0	0.95	0.87	-0.26	0.92
Total Stockholder Equity	0.99	0.95	0.91		0.96	0.97	0.85	0.8	-0.83	0.75	0.82	0.88	0.85	0.94	0.47	0.96	0.92	0.9	1.0	0.65	-0.67	0.91	0.92	0.96	-0.45	1.0
Other Liab	0.95	0.96	0.97	0.96		0.93	0.9	0.85	-0.66	0.61	0.79	0.74	0.88	0.89	0.35	0.87	0.98	0.9	0.98	0.74	-0.67	0.97	0.95	0.93	-0.44	0.96
Net Tangible Assets	0.96	0.94	0.9	0.97	0.93		0.92	0.9	-0.77	0.68	0.82	0.86	0.93	0.92	0.36	0.94	0.9	0.97	0.95	0.74	-0.64	0.89	0.89	0.99	-0.43	0.97
Property Plant And Equipment Net	0.87	0.91	0.93	0.85	0.9	0.92		0.97	-0.51	0.48	0.8	0.65	0.98	0.82	0.21	0.79	0.93	0.95	0.85	0.83	-0.52	0.92	0.91	0.9	-0.3	0.85
Current Deferred Revenue	0.83	0.86	0.9	0.8	0.85	0.9	0.97		-0.43	0.38	0.66	0.59	1.0	0.81	0.01	0.73	0.89	0.97	0.8	0.86	-0.49	0.9	0.82	0.87	-0.28	0.8
Net Debt	-0.83	-0.75	-0.58	-0.83	-0.66	-0.77	-0.51	-0.43		-0.95	-0.76	-0.98	-0.51	-0.82	-0.76	-0.93	-0.57	-0.61	-0.79	-0.3	0.38	-0.57	-0.67	-0.74	0.22	-0.83
Retained Earnings	0.79	0.74	0.58	0.75	0.61	0.68	0.48	0.38	-0.95		0.79	0.92	0.46	0.8	0.83	0.88	0.55	0.52	0.72	0.22	-0.16	0.55	0.69	0.61	0.04	0.75
Accounts Payable	0.85	0.86	0.77	0.82	0.79	0.82	0.8	0.66	-0.76	0.79		0.82	0.72	0.77	0.74	0.85	0.76	0.71	0.8	0.59	-0.37	0.73	0.92	0.79	-0.16	0.82
Cash	0.89	0.82	0.68	0.88	0.74	0.86	0.65	0.59	-0.98	0.92	0.82		0.65	0.88	0.69	0.97	0.66	0.74	0.84	0.46	-0.42	0.66	0.75	0.83	-0.24	0.88
Non Current Assets Total	0.87	0.9	0.92	0.85	0.88	0.93	0.98	1.0	-0.51	0.46	0.72	0.65		0.85	0.1	0.79	0.91	0.98	0.85	0.85	-0.5	0.92	0.86	0.91	-0.29	0.85
Non Currrent Assets Other	0.98	0.96	0.9	0.94	0.89	0.92	0.82	0.81	-0.82	0.8	0.77	0.88	0.85		0.41	0.96	0.88	0.88	0.93	0.66	-0.39	0.9	0.86	0.87	-0.15	0.94
Other Assets	0.48	0.43	0.26	0.47	0.35	0.36	0.21	0.01	-0.76	0.83	0.74	0.69	0.1	0.41		0.59	0.25	0.14	0.43	-0.02	-0.1	0.22	0.51	0.34	0.01	0.47
Cash And Short Term Investments	0.98	0.93	0.83	0.96	0.87	0.94	0.79	0.73	-0.93	0.88	0.85	0.97	0.79	0.96	0.59		0.82	0.85	0.94	0.59	-0.49	0.82	0.86	0.91	-0.27	0.96
Net Receivables	0.92	0.96	1.0	0.92	0.98	0.9	0.93	0.89	-0.57	0.55	0.76	0.66	0.91	0.88	0.25	0.82		0.9	0.94	0.77	-0.59	1.0	0.95	0.89	-0.34	0.92
Good Will	0.91	0.91	0.91	0.9	0.9	0.97	0.95	0.97	-0.61	0.52	0.71	0.74	0.98	0.88	0.14	0.85	0.9		0.89	0.82	-0.6	0.91	0.85	0.96	-0.4	0.9
Common Stock Total Equity	0.98	0.96	0.93	1.0	0.98	0.95	0.85	0.8	-0.79	0.72	0.8	0.84	0.85	0.93	0.43	0.94	0.94	0.89		0.66	-0.68	0.93	0.92	0.95	-0.45	1.0
Common Stock Shares Outstanding	0.68	0.73	0.78	0.65	0.74	0.74	0.83	0.86	-0.3	0.22	0.59	0.46	0.85	0.66	-0.02	0.59	0.77	0.82	0.66		-0.4	0.77	0.68	0.72	-0.25	0.65
Non Current Liabilities Total	-0.54	-0.47	-0.52	-0.67	-0.67	-0.64	-0.52	-0.49	0.38	-0.16	-0.37	-0.42	-0.5	-0.39	-0.1	-0.49	-0.59	-0.6	-0.68	-0.4		-0.54	-0.53	-0.74	0.96	-0.66
Inventory	0.93	0.96	1.0	0.91	0.97	0.89	0.92	0.9	-0.57	0.55	0.73	0.66	0.92	0.9	0.22	0.82	1.0	0.91	0.93	0.77	-0.54		0.93	0.87	-0.29	0.91
Other Current Assets	0.93	0.96	0.95	0.92	0.95	0.89	0.91	0.82	-0.67	0.69	0.92	0.75	0.86	0.86	0.51	0.86	0.95	0.85	0.92	0.68	-0.53	0.93		0.88	-0.28	0.92
Other Stockholder Equity	0.93	0.9	0.87	0.96	0.93	0.99	0.9	0.87	-0.74	0.61	0.79	0.83	0.91	0.87	0.34	0.91	0.89	0.96	0.95	0.72	-0.74	0.87	0.88		-0.55	0.96
Total Liab	-0.29	-0.2	-0.26	-0.45	-0.44	-0.43	-0.3	-0.28	0.22	0.04	-0.16	-0.24	-0.29	-0.15	0.01	-0.27	-0.34	-0.4	-0.45	-0.25	0.96	-0.29	-0.28	-0.55		-0.44
Net Invested Capital	0.99	0.96	0.92	1.0	0.96	0.97	0.85	0.8	-0.83	0.75	0.82	0.88	0.85	0.94	0.47	0.96	0.92	0.9	1.0	0.65	-0.66	0.91	0.92	0.96	-0.44

Click cells to compare fundamentals

Cytek Biosciences Account Relationship Matchups

Cytek Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	220.0M	463.7M	519.5M	494.5M	568.6M	389.0M
Other Current Liab	15.5M	19.2M	26.7M	26.2M	30.1M	21.0M
Total Current Liabilities	26.5M	32.2M	49.0M	56.2M	64.7M	40.7M
Total Stockholder Equity	(16.0M)	406.5M	425.3M	393.1M	452.0M	256.8M
Property Plant And Equipment Net	2.1M	5.9M	27.6M	29.3M	33.6M	35.3M
Current Deferred Revenue	4.3M	7.1M	13.0M	22.7M	26.1M	27.4M
Net Debt	(162.5M)	(364.6M)	(278.5M)	(153.2M)	(137.8M)	(144.7M)
Retained Earnings	(22.6M)	(18.2M)	(17.0M)	(29.2M)	(33.6M)	(35.2M)
Accounts Payable	2.9M	3.0M	4.8M	3.0M	3.5M	3.6M
Cash	165.2M	364.6M	296.6M	167.3M	192.4M	225.3M
Non Current Assets Total	11.4M	31.6M	65.5M	102.4M	117.8M	123.6M
Non Currrent Assets Other	1.1M	1.7M	1.4M	1.8M	2.1M	1.3M
Other Assets	8.5M	10.9M	21.8M	1.0	1.15	1.09
Cash And Short Term Investments	165.2M	364.6M	341.1M	262.4M	301.8M	256.0M
Net Receivables	18.1M	29.8M	48.9M	56.1M	64.5M	37.5M
Liabilities And Stockholders Equity	220.0M	463.7M	519.5M	494.5M	568.6M	389.0M
Non Current Liabilities Total	209.5M	24.7M	44.9M	45.2M	40.7M	66.4M
Inventory	23.0M	32.2M	48.2M	60.9M	70.0M	40.2M
Other Current Assets	2.3M	4.9M	17.9M	12.7M	14.6M	8.4M
Other Stockholder Equity	(194.3M)	423.6M	442.9M	423.4M	486.9M	511.2M
Total Liab	236.0M	56.9M	93.9M	101.4M	91.3M	96.0M
Net Invested Capital	(13.3M)	406.5M	427.6M	395.3M	454.6M	258.4M
Property Plant And Equipment Gross	2.1M	7.7M	27.6M	35.2M	40.5M	42.5M
Total Current Assets	208.6M	432.1M	454.0M	392.1M	450.9M	342.0M
Accumulated Other Comprehensive Income	65K	897K	(697K)	(1.3M)	(1.1M)	(1.1M)
Capital Stock	23K	126K	135K	131K	150.7K	95.9K
Non Current Liabilities Other	11.7M	14.9M	29.5M	18.9M	21.7M	19.7M
Net Working Capital	182.1M	399.9M	405.0M	335.8M	386.2M	301.3M
Short Term Debt	2.8M	15.3M	12.6M	3.0M	3.5M	3.3M
Intangible Assets	274K	4.7M	4.3M	23.1M	26.5M	27.9M
Common Stock	23K	126K	135K	131K	150.7K	95.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:

How To Invest In Cytek

Details

Is Cytek Stock a good investment?

Details

What is Cytek Biosciences' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.658

Earnings Share

(0.08)

Revenue Per Share

1.527

Quarterly Revenue Growth

0.073

Return On Assets

(0.03)

The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytek Price To Sales Ratio vs Pe Ratio Analysis

Price To Sales Ratio vs Pe Ratio

Price To Sales Ratio vs Pe Ratio Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Pe Ratio

Cytek Biosciences fundamental ratios Correlations

Cytek Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cytek Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 1.0	Total Current Liabilities
Inventory	+ 1.0	Total Current Liabilities
Common Stock Total Equity	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Current Deferred Revenue
Inventory	+ 1.0	Net Receivables

Cash	- 0.98	Net Debt
Retained Earnings	- 0.95	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Net Invested Capital	- 0.83	Net Debt
Net Debt	- 0.83	Total Stockholder Equity
Net Debt	- 0.83	Total Assets